{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-006294","form_type":"8-K","ticker":"GTBP","cik":"0000109657","company_name":"GT Biopharma, Inc.","filed_at":"2022-03-08T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.407729+00:00","generated_at":"2026-06-27T00:38:11.892390+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"GT Biopharma names Michael Breen Interim CEO; Gregory Berk becomes President R&D/CMO","bullets":["Michael Breen named Interim CEO effective March 2, 2022; base compensation raised to $515,000.","Gregory Berk ceases role as Interim CEO but remains President of R&D and CMO; base salary increased to $437,750.","Both appointments effective March 2, 2022; no other officer changes disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-006294","json":"https://secwatch.observer/filing/0001493152-22-006294.json","markdown":"https://secwatch.observer/filing/0001493152-22-006294.md","text":"https://secwatch.observer/filing/0001493152-22-006294.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/109657/000149315222006294/0001493152-22-006294-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/109657/000149315222006294/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T00:38:11.892390+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"950b824ea3","claim":"Michael Breen was appointed as Interim Chief Executive Officer at GT Biopharma, Inc..","evidence_excerpt":"Effective March 2, 2022, the Registrant appointed Michael Breen as the Registrant’s Interim Chief Executive Officer with an increase in his annual base compensation to $515,000.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/109657/000149315222006294/0001493152-22-006294-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"db7fef7a59","claim":"Gregory Berk changed role as President of Research & Development and Chief Medical Officer at GT Biopharma, Inc..","evidence_excerpt":"Gregory Berk, M.D. ceased serving as the Registrant’s Interim Chief Executive Officer, but will continue to serve as the Registrant’s President of Research & Development and Chief Medical Officer, with a cost-of-living increase in his annual base compensation to $437,750.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/109657/000149315222006294/0001493152-22-006294-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased"},{"label":"Role","value":"President of Research & Development and Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}